The Long & Winding Road to Weight Loss Drugs
The IMPact of untReated nOn-Valvular atrial fibrillation on short-tErm clinical and economic outcomes in the US Medicare population: the IMPROVE-AF model
Click here for the publication.
5 Steps To Prepare For A Third-Party Drug Price Evaluation
In this Life Science Leader article, Matt Sussman discusses important steps to take when preparing for a third party drug price evaluation. Sussman notes that determining fair and reasonable drug prices in the U.S. has long been a source of debate as the U.S. has lacked consistent, independent economic analysis to assess the value of […]
Pandemic Pricing: The Risks and Rewards of Fast-Tracking Value-Based Drug Evaluations
Matt Sussman, VP of Modeling & Strategy at Panalgo, discusses the risks and rewards of fast-tracking drug price evaluations in the COVID era in this Pharmacy Times article. He notes that ICER’s expedited evaluation of remdesivir raises some questions related to value-based pricing evaluations that shouldn’t be overlooked. Read the full article for Sussman’s view […]